Janney Montgomery Scott LLC Reduces Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Janney Montgomery Scott LLC reduced its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,529 shares of the medical equipment provider’s stock after selling 340 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Zimmer Biomet were worth $2,697,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ZBH. Dakota Wealth Management raised its stake in Zimmer Biomet by 1.3% during the 4th quarter. Dakota Wealth Management now owns 9,620 shares of the medical equipment provider’s stock valued at $1,016,000 after acquiring an additional 122 shares during the last quarter. Nisa Investment Advisors LLC boosted its position in Zimmer Biomet by 1.2% during the fourth quarter. Nisa Investment Advisors LLC now owns 63,099 shares of the medical equipment provider’s stock worth $6,680,000 after purchasing an additional 729 shares in the last quarter. Roberts Wealth Advisors LLC acquired a new stake in Zimmer Biomet in the fourth quarter valued at $1,954,000. Lmcg Investments LLC increased its position in shares of Zimmer Biomet by 20.4% in the fourth quarter. Lmcg Investments LLC now owns 55,949 shares of the medical equipment provider’s stock valued at $5,910,000 after buying an additional 9,484 shares in the last quarter. Finally, Ballentine Partners LLC increased its holdings in Zimmer Biomet by 18.6% during the 4th quarter. Ballentine Partners LLC now owns 4,571 shares of the medical equipment provider’s stock valued at $483,000 after acquiring an additional 716 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Analyst Ratings Changes

ZBH has been the topic of a number of analyst reports. JPMorgan Chase & Co. upgraded Zimmer Biomet from a “neutral” rating to an “overweight” rating and increased their target price for the company from $125.00 to $128.00 in a report on Tuesday, December 17th. Oppenheimer lowered their target price on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a research note on Tuesday, October 15th. Wells Fargo & Company increased their target price on Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Stifel Nicolaus increased their target price on Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research report on Thursday, January 23rd. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research report on Wednesday. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $124.11.

Zimmer Biomet Price Performance

Shares of NYSE:ZBH opened at $109.36 on Friday. The company has a market cap of $21.77 billion, a PE ratio of 20.79, a P/E/G ratio of 1.90 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $100.67 and a fifty-two week high of $133.90. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38. The firm has a 50-day simple moving average of $107.95 and a 200 day simple moving average of $108.24.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting the consensus estimate of $1.74. The company had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. Zimmer Biomet’s revenue was up 4.1% compared to the same quarter last year. During the same quarter last year, the business earned $1.65 earnings per share. On average, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were given a $0.24 dividend. The ex-dividend date of this dividend was Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.88%. Zimmer Biomet’s dividend payout ratio (DPR) is 18.25%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.